Chemotherapeutic Interventions Against Tuberculosis
AbstractTuberculosis is the second leading cause of infectious deaths globally. Many effective conventional antimycobacterial drugs have been available, however, emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has overshadowed the effectiveness of the current first and second line drugs. Further, currently available agents are complicated by serious side effects, drug interactions and long-term administration. This has prompted urgent research efforts in the discovery and development of new anti-tuberculosis agent(s). Several families of compounds are currently being explored for the treatment of tuberculosis. This review article presents an account of the existing chemotherapeutics and highlights the therapeutic potential of emerging molecules that are at different stages of development for the management of tuberculosis disease. View Full-Text
Share & Cite This Article
Shakya, N.; Garg, G.; Agrawal, B.; Kumar, R. Chemotherapeutic Interventions Against Tuberculosis. Pharmaceuticals 2012, 5, 690-718.
Shakya N, Garg G, Agrawal B, Kumar R. Chemotherapeutic Interventions Against Tuberculosis. Pharmaceuticals. 2012; 5(7):690-718.Chicago/Turabian Style
Shakya, Neeraj; Garg, Gaurav; Agrawal, Babita; Kumar, Rakesh. 2012. "Chemotherapeutic Interventions Against Tuberculosis." Pharmaceuticals 5, no. 7: 690-718.